Two separate efforts are underway to provide the public with a combination vaccine that would deliver simultaneous protections against COVID-19 and influenza. Moderna today announced its effort during a research-and-development presentation, in which a vaccine would be encoded for the COVID-19 spike protein and flu hemagglutinin glycoproteins. Novavax yesterday said its own effort, which is in a phase 1/2 clinical trial, combines within a single formulation its recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates with a patented saponin-based adjuvant. 

Related News Articles

Headline
Commenting on a forthcoming Centers for Medicare & Medicaid Services’ rule requiring COVID-19 vaccinations for workers in most health care settings…
Headline
The Centers for Medicare & Medicaid Services today announced that the agency will pay for Medicare beneficiaries’ booster doses, without cost sharing…
Headline
The Centers for Disease Control and Prevention early Friday morning opted for a broad endorsement of Pfizer COVID-19 vaccine booster shots, issuing interim…
Headline
In a study of more than 4,900 health care workers across 33 sites in 25 U.S. states, the Pfizer and Moderna COVID-19 vaccines were 89% and 96% effective,…
Headline
In AHA’s newest #MyWhy video, nine hospital employees from UAB Medicine in Alabama candidly discuss their COVID-19 vaccine experience, starting with initial…
Headline
The Centers for Medicare & Medicaid Services yesterday began publicly sharing COVID-19 vaccination rates for nursing home staff and residents on its Care…